Guangzhou Lupeng Pharmaceutical Co. Ltd. and Newave Pharmaceutical LLC have divulged (mutant) ligands reported to be useful for the treatment of cancer, autoimmune disease and inflammation.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Lisen Imprinting Pharmaceutical Technology Co. Ltd. has disclosed EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of small-cell lung (SCLC) and l lung cancer (NSCLC).
Researchers from Acerand Therapeutics (Hong Kong) Ltd. have presented Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer, metabolic diseases, cardiovascular, inflammatory, psychiatric and immunological disorders.
Researchers from the University of Texas System presented preclinical data for MC-1-F2, a direct small molecule inhibitor of forkhead box protein C2 (FOXC2). The candidate has previously shown activity in breast cancer cell lines, and the current study aimed to assess its efficacy in castration-resistant prostate cancer (CRPC).
Georgiamune Inc. announced that the FDA cleared its IND application for GIM-122, a first-in-class dual-functioning monoclonal antibody designed to target a highly novel mechanism to overcome immunotherapy resistance.
Emerging from stealth mode, new immuno-oncology company Dotbio Pte. Ltd. closed an oversubscribed $5.6 million pre-series A round to accelerate development of its multifunctional and intracellular antibody therapies.
Laboratory for Advanced Medicine & Health Group (LAMH)’s subsidiary Guangzhou Youze Biotechnology Co. Ltd. received marketing approval in China for its methylation test, which the company says is the first methylation test kit for liver cancer on the market in the world.
Regeneron Pharmaceuticals Inc. has disclosed an antibody-drug conjugate consisting of exatecan covalently linked to the antibody trastuzumab targeting HER2 through a linker reported to be useful for the treatment of cancer.